Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus

Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March 2025. Plus Gilead-Arcus TIGIT Phase 3 failure, Nektar's 20%+ alopecia surge, Trump's psychedelic executive order, AACR KRAS data from Revolution Medicines, and Novo Nordisk sickle cell Phase 3 results.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, KeloniaTherapeutics, in vivo CAR-T, cell therapy, TIGIT, Gilead, Arcus Biosciences,domvanalimab, Nektar Therapeutics, rezpegaldesleukin, alopecia areata,psychedelic drugs, ibogaine, Trump executive order, Revolution Medicines,zoldonrasib, KRAS, Merck, AACR 2026, Novo Nordisk, etavopivat, sickle celldisease, UCB, Neurona Therapeutics, Biogen, felzartamab, Kailera Therapeutics,IPO, Sanofi, Nuvaxovid, Novartis, Boehringer Ingelheim, PBM drug pricing,oncology, M&A, Lilly, Roche, BMS, Moderna